Method for predicting the development of cancers caused by human papilloma viruses (HPVs) in a test subject infected with the HPVs, comprising the following steps: 1) collecting at least two cell-containing samples from the test subject, wherein one of the at least two samples is a sample of mucosa (mucosal sample) and the other of the at least two samples is a sample of body fluid (body-fluid sample); 2) establishing whether, in the mucosal sample, the HPVs contain at least one stimulus molecule which stimulates the immune system of the test subject, by using antibodies to identify a morphological change and/or a molecular-biology change of at least one of the cells of the mucosal sample as an HPV-caused change in which the HPVs containing the stimulus molecule are involved, wherein the stimulus molecule contemplated is the L1 protein of the capsid of the HPVs of type 16 and the antibodies are specific against the stimulus molecule; 3) establishing whether the body-fluid sample contains endogenous antibodies against the HPVs containing the stimulus molecule, by mixing the body-fluid sample with a reagent which substantially consists of a predefined amount of physiologically effective liquid and a predefined amount of at least one antigen and subsequently supplying the mixture to an analysis which uses a measurable and/or user-perceivable change, wherein the antigen is reactive with regard to antibodies which are present in the body-fluid sample and which are specific against the HPV16 stimulus molecule (HPV16L1-specific antibodies); 4) making an evaluation to the effect that, in the event of establishing the stimulus molecule in step and in the event of establishing the endogenous antibodies in step, it is predicted that the development of cancers caused by the HPVs contemplated is prevented with very high probability by the immune system of the test subject. 1) collecting at least two cell-containing samples from the test subject, wherein one of the at least two samples is a sample of mucosa (mucosal sample) and the other of the at least two samples is a sample of body fluid (body-fluid sample); 2) establishing whether, in the mucosal sample, the HPVs contain at least one stimulus molecule which stimulates the immune system of the test subject, by using antibodies to identify a morphological change and/or a molecular-biology change of at least one of the cells of the mucosal sample as an HPV-caused change in which the HPVs containing the stimulus molecule are involved, wherein the stimulus molecule contemplated is the L1 protein of the capsid of the HPVs of type 16 and the antibodies are specific against the stimulus molecule; 3) establishing whether the body-fluid sample contains endogenous antibodies against the HPVs containing the stimulus molecule, by mixing the body-fluid sample with a reagent which substantially consists of a predefined amount of physiologically effective liquid and a predefined amount of at least one antigen and subsequently supplying the mixture to an analysis which uses a measurable and/or user-perceivable change, wherein the antigen is reactive with regard to antibodies which are present in the body-fluid sample and which are specific against the HPV16 stimulus molecule (HPV16L1-specific antibodies); 4) making an evaluation to the effect that, in the event of establishing the stimulus molecule in step and in the event of establishing the endogenous antibodies in step, it is predicted that the development of cancers caused by the HPVs contemplated is prevented with very high probability by the immune system of the test subject.